Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung.
Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung.
复制标题
整合素α3表达减少是肺腺癌患者预后不良的一个因素。
DOI：
--
复制
发表时间：
1998
影响因子：
45.3
通讯作者：
M. Miyake
中科院分区：
文献类型：
--
作者：
M. Adachi;T. Taki;C. Huang;M. Higashiyama;O. Doi;T. Tsuji;M. Miyake
目的
本研究探讨了整合素α 3与运动相关蛋白（MRP-1）、分化抗原9（CD 9）基因表达在非小细胞肺癌（NSCLC）中的可能关系，并评估了整合素α 3表达的预后意义。
患者和方法
我们采用定量逆转录聚合酶链反应（RT-PCR）和免疫组织化学方法对151例NSCLC患者切除肿瘤组织中整合素α 3和MRP-1/CD 9的表达进行了回顾性研究。
结果
整合素α 3/β-肌动蛋白表达的比值范围为0 - 5.87（平均值为0.80;中位数为0.70）。使用0.7的截止值，有78例（52%）整合素α 3阳性肿瘤和73例（48%）整合素α 3表达降低的肿瘤。免疫组化结果与RT-PCR结果一致，88%无差异。如有不一致，则采用RT-PCR结果对标本进行分类。整合素α 3基因表达与MRP-1/CD 9基因表达无关。整合素α 3的表达与患者的临床特征之间无显著相关性。整合素α 3阳性NSCLC患者的总体生存率仅略高于整合素α 3表达降低的个体（55.9%对47.1%; P = 0.085）。相比之下，整合素α 3阳性腺癌患者的总生存率明显高于基因表达降低的患者（54.4%对35.2%; P = 0.004）。非小细胞肺癌和腺癌的考克斯回归模型的多变量分析表明，整合素α 3表达与总生存率的相关性（分别为P = 0.0188和P = 0.0008）优于其他变量，淋巴结状态除外。
结论
肺癌组织中整合素α 3与MRP-1/CD 9基因表达无明显相关性。然而，整合素α 3表达减少是腺癌患者预后不良的因素。
PURPOSE
We investigated the possible association between integrin alpha3 and motility-related protein (MRP-1), cluster of differentiation antigen 9 (CD9) gene expression in non-small-cell lung cancer (NSCLC) and evaluated the prognostic significance of integrin alpha3 expression.
PATIENTS AND METHODS
We performed a retrospective study of integrin alpha3 and MRP-1/CD9 expression in resected tumor tissues from 151 NSCLC patients using quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry.
RESULTS
The ratio of integrin alpha3/beta-actin expression ranged from 0 to 5.87 (mean was 0.80; median, 0.70). Using the cutoff value of 0.7, there were 78 (52%) integrin alpha3-positive tumors and 73 (48%) tumors with reduced integrin alpha3 expression. The immunohistochemical results agreed well with those of the RT-PCR assays, and 88% had no discrepancy. In case of discrepancy, the results of RT-PCR were used in specimen classification. Integrin alpha3 gene expression was independent from MRP-1/CD9 gene expression. No significant association was found between integrin alpha3 expression and the patients' clinical characteristics. The overall survival rate of patients with integrin alpha3-positive NSCLCs was only slightly better than that of individuals whose tumors had reduced integrin alpha3 expression (55.9% v 47.1%; P = .085). By comparison, the overall survival rate of patients with integrin alpha3-positive adenocarcinomas was strikingly greater than in those whose tumors had reduced gene expression (54.4% v 35.2%; P = .004). Multivariate analysis with the Cox regression model of NSCLC and adenocarcinoma indicated that integrin alpha3 expression correlated better (P = .0188 and P = .0008, respectively) with the overall survival rate than other variables, except lymph node status.
CONCLUSION
No significant association was found between integrin alpha3 and MRP-1/CD9 gene expression in lung cancer. However, reduced integrin alpha3 expression is a poor prognosis factor in patients with adenocarcinomas.